MEDADVISOR LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.295 AUD | 0.00% |
|
+9.26% | +37.21% |
| 04-24 | MedAdvisor Operating Revenue Rises 42% to AU$24.2 Million in March Quarter | MT |
| 04-23 | MedAdvisor's Gross Profit Climbs 48.5% in Fiscal Q3, Revenue Rises 42.4% | MT |
| Sales 2024 * | 118M 77.56M 6.19B | Sales 2025 * | 136M 89.36M 7.13B | Capitalization | 162M 106M 8.49B |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -1.31M -105M | Net income 2025 * | -1M -656K -52.32M | EV / Sales 2024 * | 1.31 x |
| Net cash position 2024 * | 7.55M 4.95M 395M | Net cash position 2025 * | 11.6M 7.61M 607M | EV / Sales 2025 * | 1.11 x |
| P/E ratio 2024 * |
-59
x | P/E ratio 2025 * |
-80.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.69% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +9.26% | ||
| Current month | +7.27% | ||
| 1 month | +7.27% | ||
| 3 months | +5.36% | ||
| 6 months | +55.26% | ||
| Current year | +37.21% |
1 week
0.27
0.32
1 month
0.240.32
Current year
0.220.35
1 year
0.160.35
3 years
0.130.42
5 years
0.130.68
10 years
0.130.68
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Ratliff
CEO | Chief Executive Officer | - | 14/07/22 |
Ancila Desai
DFI | Director of Finance/CFO | - | 16/10/22 |
Craig Schnuriger
CTO | Chief Tech/Sci/R&D Officer | - | 29/06/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Linda Jenkinson
CHM | Chairman | - | 27/02/22 |
Kevin Hutchinson
BRD | Director/Board Member | - | 22/11/22 |
Richard Ratliff
CEO | Chief Executive Officer | - | 14/07/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.295 | 0.00% | 98 210 |
| 26/04/24 | 0.295 | -3.28% | 162,929 |
| 24/04/24 | 0.305 | +5.17% | 83,089 |
| 23/04/24 | 0.29 | +7.41% | 1,412,747 |
| 22/04/24 | 0.27 | +3.85% | 228,088 |
Delayed Quote Australian S.E., April 29, 2024 at 06:54 am
More quotes
MedAdvisor Limited is an Australia-based company that is engaged in digital medication adherence solutions. The Companyâs segments include Australia, the United States, the United Kingdom and Asia Operations. The Companyâs products suite includes Medication Management Application, PlusOne Pharmacy Software and Pharma Patient Experience Platform. The Medication Management Application connects to the pharmacy from the mobile phone. The Companyâs subsidiaries include MedAdvisor International Pty. Ltd., Health Enterprises 2 Pty. Ltd., MedAdvisor Welam UK Ltd., MedAdvisor Welam USA Inc. and Adheris, LLC.
Calendar
28/08/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.295
AUD
Average target price
0.4233
AUD
Spread / Average Target
+43.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.21% | 106M | |
| +4.36% | 32.47B | |
| +16.51% | 7.45B | |
| +21.93% | 3.89B | |
| -16.29% | 3.17B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -35.42% | 902M | |
| -0.13% | 893M | |
| -24.12% | 857M |
- Stock Market
- Equities
- MDR Stock
